Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumour peptide-pulsed dendritic cell vaccine - Tella

Next Previous
Drug Profile

Tumour peptide-pulsed dendritic cell vaccine - Tella

Alternative Names: Dendritic-cell-vaccine-Tella; MUC1-WT1-peptide-loaded-dendritic-cell-vaccine-Tella; Peptide-pulsed-dendritic-cell-vaccine-Tella; TLP0-001; Vaccell - Tella; WT1 and MUC1 peptide-pulsed dendritic cell vaccine - Tella

Latest Information Update: 28 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tella
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I/II Biliary cancer; Malignant melanoma
  • No development reported Allergic rhinitis; Autoimmune disorders; Liver cancer; Oesophageal cancer

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for phase-I development in Oesophageal-cancer in Japan (Parenteral)
  • 15 Feb 2021 Tella completes a phase I/II trial in Biliary cancer (In adults, In the elderly) in Japan (Parenteral) (UMIN000010388)
  • 15 Feb 2021 Tella completes a phase I/II trial in Pancreatic cancer (In adults, In the elderly) in Japan (Parenteral) (UMIN000010388)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top